Hematologic Malignancies and Cellular Therapy

Danielle Marie Brander, MD

Assistant Professor of Medicine

Member of the Duke Cancer Institute

Campus mail 2400 Pratt St Suite 5000, Durham, NC 27710

Phone (919) 668-1000

Email address danielle.brander@duke.edu

In Their Words

Education and Training

Resident, Internal Medicine, Duke University School of Medicine, 2007 - 2010
M.D., Duke University School of Medicine, 2007

Grants

A Phase 1 study of ublituximab and umbralisib in combination with targeted immunotherapy in patients with relapsed-refractory CLL or Richter's transformation of CLL
A PHASE I STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETIC AND PHARMACODYNAMIC PROPERTIES OF ORALLY ADMINISTERED APG-2575 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
A Phase 3, Randomized study of Zanubrutinnig (BGB-3111) compared with Ibrutinig in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
A Phase I Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies
An Open-Label, Phase 1 Safety and Phase 2 Randomized Study of JCAR017 in Subjects with Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma (017004)
A Phase 1, Open-label, study of Voruciclib in Subjects with Relapsed and/or Refractory B Cell Malignancies after failure of prior standard therapies
TP-0903-102 A Combined Phase 1/2 Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of TP-0903 in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)
BGB-3111-304 An International, Phase 3, Open-label, Randomized Study of BGB-3111 Compared with Bendamustine plus Rituximab in Patients with Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 1a/1b Study of a Novel BTK Inhibitor, DTRMWXHS-12, and Combination Products, CTRM-505 and DTRM-555, in Patients with Chronic Lymphocytic Leukemia or Other B-Cell Lymphomas
An Open Label Compassionate Use Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently receiving Treatment on Ublituximab and/or TGR-1202 Trials with B-cell Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia.
DFCI Obinutuzumab and Ibrutinib Protocol # 15-283
Exercise training to promote improved immune resilience in adults with chronic lymphocytic leukemia - a randomized control trial
A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients with Chronic Lymphocytic Leukemia (CLL) who are Intolerant to Prior BTK or P13K-Delta Inhibitor Therapy
A Multi¿Center, Open¿Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination with TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304
A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination with TGR-1202 Compared to Obinutuzumab in Combination with Chlorambucil in Patients with Chronic Lymphocytic Leukemia (CLL)
Phase III study of ACP-196 vs Ibrutinib in High Risk CLL
Phase 3 Study of Ublituximab in combination with Ibrutinib compared to Ibrutinib Alone in CLL pts.
A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia.

Publications

Mato, Anthony R., Lindsey E. Roeker, Ryan Jacobs, Brian T. Hill, Nicole Lamanna, Danielle Brander, Mazyar Shadman, et al. “Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective Strategy.” Clin Cancer Res 26, no. 14 (July 15, 2020): 3589–96. https://doi.org/10.1158/1078-0432.CCR-19-3815.

PMID

32198151

Full Text

Sung, Anthony D., Shekeab Jauhari, Sharareh Siamakpour-Reihani, Arati V. Rao, Janet Staats, Cliburn Chan, Everett Meyer, et al. “Microtransplantation in older patients with AML: A pilot study of safety, efficacy and immunologic effects.” Am J Hematol 95, no. 6 (June 2020): 662–71. https://doi.org/10.1002/ajh.25781.

PMID

32162718

Full Text

Sitlinger, Andrea, Danielle M. Brander, and David B. Bartlett. “Impact of exercise on the immune system and outcomes in hematologic malignancies.” Blood Adv 4, no. 8 (April 28, 2020): 1801–11. https://doi.org/10.1182/bloodadvances.2019001317.

PMID

32343800

Full Text

Eyre, Toby A., Lindsey E. Roeker, Christopher P. Fox, Satyen H. Gohill, Renata Walewska, Harriet S. Walter, Francesco Forconi, et al. “The efficacy and safety of venetoclax therapy in elderly patients with relapsed, refractory chronic lymphocytic leukaemia.” Br J Haematol 188, no. 6 (March 2020): 918–23. https://doi.org/10.1111/bjh.16271.

PMID

31682002

Full Text

Eichenberger, Emily M., Jennifer Saullo, Danielle Brander, Shih-Hsiu Wang, John R. Perfect, and Julia A. Messina. “A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy.” Med Mycol Case Rep 27 (March 2020): 17–21. https://doi.org/10.1016/j.mmcr.2019.12.007.

PMID

31879587

Full Text

Weinberg, J Brice, Danielle M. Brander, Dale J. Christensen, and Daphne R. Friedman. “Post-translational regulation could be determine functional differences between SET alpha and beta isoform - Response to Cristóbal et al.” Br J Haematol 186, no. 4 (August 2019): 637. https://doi.org/10.1111/bjh.15934.

PMID

31044417

Full Text

Davids, Matthew S., Danielle M. Brander, Haesook T. Kim, Svitlana Tyekucheva, Jad Bsat, Alexandra Savell, Jeffrey M. Hellman, et al. “Ibrutinib plus fludarabine, cyclophosphamide, and rituximab as initial treatment for younger patients with chronic lymphocytic leukaemia: a single-arm, multicentre, phase 2 trial.” Lancet Haematol 6, no. 8 (August 2019): e419–28. https://doi.org/10.1016/S2352-3026(19)30104-8.

PMID

31208944

Full Text

Roeker, Lindsey E., Christopher P. Fox, Toby A. Eyre, Danielle M. Brander, John N. Allan, Stephen J. Schuster, Chadi Nabhan, et al. “Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.” Clin Cancer Res 25, no. 14 (July 15, 2019): 4264–70. https://doi.org/10.1158/1078-0432.CCR-19-0361.

PMID

31004001

Full Text

Mato, Anthony R., Lindsey E. Roeker, Toby A. Eyre, Chadi Nabhan, Nicole Lamanna, Brian T. Hill, Danielle M. Brander, et al. “A retrospective comparison of venetoclax alone or in combination with an anti-CD20 monoclonal antibody in R/R CLL.” Blood Adv 3, no. 10 (May 28, 2019): 1568–73. https://doi.org/10.1182/bloodadvances.2019000180.

PMID

31101647

Full Text

Brander, Danielle M., Daphne R. Friedman, Alicia D. Volkheimer, Dale J. Christensen, Laura Z. Rassenti, Thomas J. Kipps, Eross Guadalupe, et al. “SET alpha and SET beta mRNA isoforms in chronic lymphocytic leukaemia.” Br J Haematol 184, no. 4 (February 2019): 605–15. https://doi.org/10.1111/bjh.15677.

PMID

30443898

Full Text

Danielle Marie Brander, MD

Education and Training

Grants

Publications

Pages